Molbio Diagnostics IPO — GMP, Subscription, Review & Score

Molbio Diagnostics

MAINBOARD IPO · NSE, BSE · ✅ LISTED

FINMINUTES IPO SCORE 63/100

₹768–807

Price Band

Issue ₹940 cr · Lot 18

FinMinutes Deep Business Model & Edge

Molbio Diagnostics Limited is an innovative point-of-care (POC) diagnostics company that designs, develops, and manufactures portable, real-time PCR platforms and diagnostic test kits. The company generates recurring revenue primarily through the sale of its 'Truenat' test kits and devices to public healthcare programs, private laboratories, and hospitals.

What this company actually does — full breakdown ▾

Incorporated in 2000, Molbio Diagnostics Limited is a pioneer in the point-of-care (POC) molecular diagnostics space in India. Its flagship product, the 'Truenat' platform, is a battery-operated, portable real-time PCR system that performs automated sample preparation and analyzer functions, delivering results in under an hour even in resource-limited settings. The company has commercialized molecular testing for 30 diseases with 43 assays as of March 31, 2026, including tuberculosis, COVID-19, Hepatitis B/C, HIV, and HPV. Molbio relies heavily on public health programs, deriving 84.56% of its finished goods revenue in FY26 from Indian central/state governments and international aid agencies. The company's top ten customers, including the Central Medical Services Society, generated 83.26% of FY26 finished goods revenue. Molbio operates six manufacturing facilities in India (in Goa, Bengaluru, and Visakhapatnam) and is highly research-focused, conducting R&D through its wholly-owned subsidiary, Bigtec Private Limited. It also offers digital pathology, radiology, and breast health screening through subsidiaries like Prognosys and OptraScan. With institutional backing from Temasek and Motilal Oswal, the company has commercialized its products globally, exporting to more than 90 countries.

Truenat Devices — Refers to the sale of Truenat Platforms (workstations) comprising Trueprep and Truelab devices along with accessories such as printers and micropipettes. This segment generated ₹2,032.84 million, accounting for 14.06% of revenue from operations in FY26.
Truenat Test Kits — Refers to disease-specific, ready-to-use micro PCR chips, reagents, and cartridges. This segment is the core driver of recurring revenues, generating ₹10,348.20 million or 71.58% of revenue from operations in FY26, with tuberculosis tests contributing 70.20% of finished goods sales.
Other Products and Services — Includes radiology equipment (x-ray systems under Prognosys) and digital pathology solutions (digital pathology scanners under OptraScan), animal health screening, and other trading income.

Moat / Edge

Molbio has created a strong entry barrier and oligopolistic positioning with its 'Truenat' platform, which underwent 13 years of R&D to obtain ICMR certification. Its Truenat test chip for diagnosing TB is the only one developed by an Indian company (and one of only two globally) endorsed by the WHO for initial diagnosis and rifampicin resistance detection. The platform operates on a razor-and-blade model, generating high-margin, recurring revenues from proprietary disease-specific test kits that must be used with the device.

The Offer

Open – Close2026-08-10 – 2026-08-12

Price Band₹768–807

Lot Size18

Min Investment—

Issue Size₹940 cr

Fresh Issue₹200 cr

Offer for Sale—

ListingNSE, BSE

Follow the Money — Use of Proceeds

Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by our wholly-owned Subsidiary, Bigtec, and connected office space for our Company, Subsidiaries and Associate — ₹105.54 cr
Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit — ₹72.28 cr
General corporate purposes

Valuation at the Offer Price

P/E at ₹807 upper band54.6xour arithmetic, on latest restated EPS

Peer median P/E63.0x

Against peers −13% discount to median

RoNW14.3%

The filing does not print a single headline multiple, so this one is ours: the upper band divided by the latest restated earnings per share — the same arithmetic the “Basis for the Offer Price” section performs. It is struck on pre-issue earnings; where the issue creates new shares, the post-issue multiple is computed in the workings below. The peer group is the one the filing itself names. A premium is not the same thing as expensive and a discount is not the same thing as cheap — the peer table and the reasons sit further down this page.

FinMinutes IPO Score — How It's Built

Transparent, deterministic, computed from the filing — not an opinion. Open any component below to see exactly what it measures and what it is worth. Components with no disclosed input are dropped from the weighting entirely rather than held at an invented neutral, because a constant inside a weighted average is not neutral — it quietly drags every score toward the middle. Weighted across 5 live components.

Score coverage 88%

88% of the designed weighting had real data behind it on this issue. Not yet scored here: Anchor Quality. A lower coverage figure does not mean a worse company — it means we are standing behind less of the picture, and you should read the findings below rather than the headline number.

Issue Structure 70/100

How this is measured12%

Whether fresh capital actually enters the business. A predominantly offer-for-sale issue is marked down ONLY when the financials are weak. A profitable, cash-rich company selling down is treated as neutral, not penalised, because it does not need the money.

Financial Quality 70/100

How this is measured32%

Driven by the models battery run on the filing's own restated numbers: the Piotroski fundamental tests (scored out of those we could actually run), the Altman Z-double-prime solvency zone, and the direction of profit across the disclosed period. It is not a single yes/no on last year's profit.

Valuation Vs Peers 55/100

How this is measured10%

The post-issue earnings multiple against the peer median disclosed in the filing. A discount to the median scores well and a premium scores badly. When the filing does not disclose comparable peer multiples, this component is dropped from the weighting rather than held at a made-up neutral.

Underwriter Quality 75/100

How this is measured6%

A proxy for syndicate strength, based today only on how many lead managers are on the issue: 75 where three or more banks are involved, 60 otherwise. We have not built a bank-by-bank track record, so treat this as a rough signal. When the filing does not disclose the syndicate, this component is dropped from the weighting rather than guessed.

Governance Forensics 52/100

How this is measured28%

Starts at 100 and loses points for every material finding: 12 for a flagged finding, 4 for a noted one. Two kinds feed it. DERIVED findings are computed from the filed numbers against stated thresholds — operating cash negative while profit is positive, related-party revenue above 15% of total, revenue rising while profit falls, goodwill above 30% of net worth, receivables growing more than 1.3x faster than sales, cash below half of short-term debt. Those are reproducible: the same filing gives the same answer every time, and the rule is printed beside the finding. READ findings come from the forensic sweep of the notes. Contingent liabilities, related-party intensity, customer concentration, litigation, auditor qualifications, statutory dues, promoter funding. Findings that record the ABSENCE of a problem — no litigation pending, an unmodified audit opinion — deduct nothing. This is the component our forensic read drives directly, and it moves most between companies.

3-Year Financial & Growth Trend

Metric	FY26	FY25	FY24
Revenue (₹ Cr)	1445.687	1020.418	836.561
Net Profit (₹ Cr)	164.14	138.579	83.542
PAT Margin	11.35%	13.58%	9.99%

Revenue Breakdown

Revenue from sale of test kits: 71.58%
Revenue from sale of devices: 14.06%
Others (including subsidiary revenues and other operating revenues): 14.36%

Market Context

NOT part of the FinMinutes Score

The Score above is what the filing says. Everything in this box is what the crowd says. We keep them apart on purpose — every other site blends the two and calls the result a rating. Demand is real information, but it is information about the market, not about the company, and it changes by the hour while the company does not.

Momentum100/100from live subscription

Total81.7xsubscribed

QIB—xbids land late

Retail—x

GMP₹110unofficial, grey market

The book is running ahead of the filing.

The market is bidding this issue enthusiastically. The headline financials look strong, but our forensic read of the filing is not clean — the risk band is high and the footnotes carry material flags. That gap is the fact worth noticing. Strong demand is information about the market; the flags are information about the company, and the two are not saying the same thing here. Read the Forensic Findings below before the momentum decides it for you.

Subscription is low early in a book and high at the end, because most bids arrive in the final hours. A number read on day one says more about the clock than the company — which is precisely why it is not in the Score. GMP is unofficial, unregulated, and easily moved. Neither is a recommendation.

Applying, and Who Handles the Allotment

Cut-off price₹807.00

Minimum retail application₹14,526

Check allotment status on the registrar’s own portal → We link the registrar directly rather than mirroring the form.

Deep Financials

Revenue, EBITDA and profit are what every listing site prints. Below are the full restated statements as disclosed, the ratios we compute from them, and a DuPont decomposition of the return on equity. A prospectus carries three years, not ten — that is the document’s ceiling, and within it we go as deep as it allows.

Income StatementThe profit and loss as filed, then what we derive from it — kept apart.

Statutory order, exactly as restated in the filing. Finance cost and depreciation sit inside Total Expenses under Ind AS, which is why they are listed among the expense lines here rather than below the total. The expense rows sum to the total. Rows the filing does not disclose separately are omitted rather than left blank.

Income Statement — as filed (₹ Cr)	FY26	FY25	FY24
Revenue from Operations	1,445.69	1,020.42	836.56
Other Income	9.48	7.52	4.10
Total Income	1,455.17	1,027.94	840.66
Cost of Materials Consumed	569.92	434.77	319.93
Employee Benefit Expense	145.23	102.79	63.89
Finance Cost	33.47	17.66	14.45
Depreciation & Amortisation	63.64	44.55	41.01
Other Expenses	402.84	240.57	198.07
Total Expenses	1,221.35	820.41	657.83
Profit Before Tax	231.14	194.43	129.64
Tax Expense	67.00	55.85	46.10
Profit After Tax	164.14	138.58	83.54
EPS - Basic	14.77	12.87	9.05
EPS - Diluted	14.77	12.87	9.04

Below this line the figures are ours, not the filing's. Ind AS has no EBITDA or EBIT line. We reconstruct them from disclosed items — EBIT as profit before tax plus finance cost, less any exceptional item and share of associate profit sitting below the operating line; EBITDA as EBIT plus depreciation. The working is in the Formula Notebook.

Derived by us (₹ Cr)	FY26	FY25	FY24
EBITDA	328.24	256.64	185.09
EBIT	264.60	212.09	144.09

Balance SheetWhat the company owns, owes, and is worth on paper.

Balance Sheet (₹ Cr)	FY26	FY25	FY24
Share Capital	11.28	2.26	2.25
Reserves & Surplus	1,158.06	966.14	821.13
Net Worth	1,144.68	952.95	807.94
Long-term Borrowings	212.41	6.14	15.12
Short-term Borrowings	200.23	117.02	159.45
Total Borrowings	412.64	123.16	174.58
Trade Payables	199.50	230.21	93.99
Current Liabilities	557.36	441.67	342.76
Total Liabilities	839.65	494.27	392.22
Property, Plant & Equipment	248.08	204.06	167.91
Capital Work in Progress	11.32	27.33	1.58
Intangible Assets	170.81	52.78	70.42
Investments	5.98	45.57	5.99
Inventories	449.26	435.91	315.14
Trade Receivables	408.74	271.66	425.45
Cash & Equivalents	355.53	114.75	22.11
Current Assets	1,384.84	929.83	823.16
Total Assets	2,148.42	1,461.56	1,221.06

Cash FlowWhere the cash actually went. Often the most honest statement of the three.

Cash Flow (₹ Cr)	FY26	FY25	FY24
Net Cash from Operating Activities	50.39	287.10	9.57
Capital Expenditure	50.02	54.66	16.11
Net Cash from Investing Activities	-93.22	-122.65	-45.01
Net Cash from Financing Activities	276.07	-26.15	-31.55
Net Change in Cash	233.23	138.30	-66.99

Ratio AnalysisProfitability, leverage, liquidity, efficiency and earnings quality — computed by us.

Every ratio below is computed by us from the line items the company disclosed — not copied from anywhere. The arithmetic is standard; the point is that somebody actually did it. Blank cells mean the filing did not disclose the inputs, and we would rather show a gap than invent a number.

Ratio	FY26	FY25	FY24
Profitability
EBITDA Margin (%)	22.6	25	22
EBIT Margin (%)	18.2	20.6	17.1
PAT Margin (%)	11.4	13.6	10
Return on Equity (%)	14.3	14.5	10.3
Return on Capital Employed (%)	17	19.7	14.7
Return on Assets (%)	7.6	9.5	6.8
Leverage
Debt / Equity (x)	0.36	0.13	0.22
Net Debt / EBITDA (x)	0.17	0.03	0.82
Interest Coverage (x)	7.91	12.01	9.97
Liquidity
Current Ratio (x)	2.48	2.11	2.4
Quick Ratio (x)	1.68	1.12	1.48
Efficiency
Asset Turnover (x)	0.67	0.7	0.69
Receivable Days	103	97	186
Inventory Days	288	366	360
Payable Days	128	193	107
Cash Conversion Cycle (days)	263	270	439
Quality of Earnings
Operating Cash Flow / PAT (x)	0.31	2.07	0.11
Accruals Ratio (%)	5.3	-10.2	6.1
Capex / Depreciation (x)	0.79	1.23	0.39
Inventory and payable days are measured against cost of goods (materials consumed + purchases of stock-in-trade + change in inventories). Receivable days against revenue.

DuPont DecompositionWhy the return on equity is what it is: margin, efficiency, or leverage.

A headline return on equity tells you what. The DuPont decomposition tells you why — whether the return is earned through margin, through asset efficiency, or simply through leverage. Two companies can post an identical ROE for opposite reasons, and only one of them is safe.

Component	FY26	FY25	FY24
Net Margin (PAT / Revenue)	11.4%	13.6%	10%
Asset Turnover (Revenue / Assets)	0.67x	0.7x	0.69x
Equity Multiplier (Assets / Net Worth)	1.88x	1.53x	1.51x
= Return on Equity	14.3%	14.5%	10.3%
Tax Burden (PAT / PBT)	0.71x	0.71x	0.64x
Interest Burden (PBT / EBIT)	0.87x	0.92x	0.9x
Operating Margin (EBIT / Revenue)	18.3%	20.8%	17.2%

Computed from the disclosed statements. Where the filing omits an input, the row is left blank rather than estimated.

Quality of EarningsWhat the statements say when you read them against each other.

What the statements say once you read them against each other. These are observations, not verdicts — every one is arithmetic on the numbers the company itself disclosed, and each is stated so you can go and check it in the filing.

Operating cash flow was only 0.31x reported profit in FY26. Less than half of the profit on the income statement arrived as cash.
Receivable days fell from 186 to 103. Collections improved over the disclosed period.

Forensic ModelsBeneish, Altman, Piotroski and the Montier C-score — plus our own final-year check.

Beneish M-Score

M = -1.89

An eight-variable model built to detect earnings manipulation, and built to run on exactly two consecutive years — which is what a prospectus gives us. It belongs here more than anywhere: a company about to list has the maximum possible incentive to have dressed up the very years it is about to show you. A score above −1.78 is the threshold at which the model says the accounts merit a closer look. It is a screening signal, not an accusation, and it was calibrated on listed companies elsewhere. Read the eight components, not just the total.

Component	Value	What it captures
DSRI Days Sales in Receivables Index `(Receivables_t / Sales_t) / (Receivables_t-1 / Sales_t-1)`	1.062	Above 1 means receivables grew faster than sales. Revenue may be being recognised ahead of collection.
GMI Gross Margin Index `GrossMargin_t-1 / GrossMargin_t`	0.947	Above 1 means margins deteriorated. A firm with worsening prospects has more incentive to manipulate.
AQI Asset Quality Index `AQ_t / AQ_t-1, where AQ = 1 - (CurrentAssets + PPE) / TotalAssets`	1.07	Above 1 means a rising share of assets is soft (neither current nor fixed) — capitalised costs can hide here.
SGI Sales Growth Index `Sales_t / Sales_t-1`	1.417	Growth is not manipulation. But high-growth firms face more pressure to keep the streak going.
DEPI Depreciation Index `DepRate_t-1 / DepRate_t, where DepRate = Dep / (Dep + PPE)`	0.878	Above 1 means assets are being depreciated more slowly — a quiet way to lift reported profit.
SGAI SG&A Index `(SGA_t / Sales_t) / (SGA_t-1 / Sales_t-1), SGA proxied as employee cost + other expenses`	1.127	A proxy, because filings rarely break out SG&A cleanly. Read it as a direction, not a precise figure.
LVGI Leverage Index `Leverage_t / Leverage_t-1, where Leverage = (CurrentLiab + LongTermDebt) / TotalAssets`	1.169	Above 1 means leverage rose. Debt covenants create pressure to hit numbers.
TATA Total Accruals to Total Assets `(PAT - CashFromOperations) / TotalAssets`	0.0529	The gap between reported profit and cash generated. The single heaviest term in the model — and the one that catches profit that never became cash.

M = -1.89, below the −1.78 threshold. The model does not flag these accounts.

Altman Z″-Score (emerging markets)

Z″ = 9.79 · Safe

A distress-prediction model. We use the Z″ variant deliberately: the original Z was calibrated on American manufacturers and misleads badly on Indian services companies. Above 2.6 is the safe zone, 1.1 to 2.6 is grey, below 1.1 is the distress zone. Like every model of its kind it is a screen, not a prophecy.

X1 — Working Capital / Total Assets	0.385
X2 — Reserves / Total Assets	0.539
X3 — EBIT / Total Assets	0.123
X4 — Net Worth / Total Liabilities	1.363
Z″ = 3.25 + 6.56·X1 + 3.26·X2 + 6.72·X3 + 1.05·X4	9.79

X2 is meant to read retained earnings. The filing reports Other Equity, which also holds securities premium paid in by investors, so X2 here runs on reserves and reads higher than true retained earnings would. The more premium the company has raised before listing, the more Z″ is flattered.

Piotroski F-Score (adapted)

4 / 8

Nine yes-or-no tests of fundamental strength — except we run eight. One of the original nine asks whether the company issued new shares, which is plainly absurd to ask of a company whose entire purpose at this moment is to issue shares. We drop that test, and we would rather tell you that than quietly fudge it.

✓Positive return on assets
✓Positive operating cash flow
✗Return on assets improving
✗Cash flow exceeds profit (quality of earnings)
✗Long-term leverage decreasing
✓Current ratio improving
✓Gross margin improving
✗Asset turnover improving

Montier C-Score

4 of 6 signs

Six yes-or-no signs that reported profit may be running ahead of the business, from James Montier’s 2008 screen, read here for FY26 against FY25. Each is a direction in the statements, not a judgement. Several together are a reason to read the accounting policies and notes closely; none on its own means anything is wrong, and growing companies trip some of them honestly.

●Gap between profit and operating cash flow widening · PAT − CFO: ₹-148.5 cr in FY25, ₹113.8 cr in FY26
●Receivable days rising · 97 days in FY25, 103 days in FY26
○Inventory days rising · 366 days in FY25, 288 days in FY26 (on cost of goods)
●Other current assets rising against revenue · 10.5% of revenue in FY25, 11.9% in FY26 (current assets less cash, receivables and inventory)
○Depreciation falling against fixed assets · 21.8% of net block in FY25, 25.7% in FY26
●Total assets growing more than 10% a year · 47.0% in FY26

The Final-Year Check

ours

Not from any textbook. The hockey stick in the last year before a filing is the oldest pattern in this business, and nobody publishes it. So we measure it: how the final disclosed year compares with the years behind it. Real acceleration looks exactly the same on the page as a flattering one — which is precisely why it is worth naming rather than assuming either way.

Cash conversion fell sharply in the final year: operating cash flow was 0.31x profit in FY26, against 2.07x in FY25. Profit rose; the cash behind it did not follow at the same rate.

Ratios Nobody Prints

Contingent liabilities / Net worth: 14.7%
Contingent liabilities of 168.74 cr against a net worth of 1,144.68 cr — 14.7% of what the company is worth on paper. These are obligations that sit off the balance sheet but could land on it. What they consist of matters as much as the size: a corporate guarantee to a subsidiary is a different animal from a disputed tax demand, and the filing says which.
Cash / Short-term borrowings: 1.78x
Short-term borrowings of 200.23 cr against cash of 355.53 cr. Debt that must be refinanced within a year is only comfortable while lenders stay comfortable.
Promoter remuneration / PAT: 6.4%
Managerial remuneration to the promoter group was 10.49 cr against a profit of 164.14 cr. This is a legitimate cost — but it is also a route by which value leaves a company before it ever reaches a minority shareholder.

What the Price RequiresThe profit the offer price needs, at three hurdle rates. A restatement of the price, not a view on it.

At the upper band of ₹807.00, the market value is ₹8,968 cr. A buyer who wants a given return each year from a business that never grows needs annual profit of market value × that return. The three rates are round hurdle rates, not this company’s cost of capital, so pick the one that is yours. The years columns assume profit compounds from the FY26 figure and the price stands still. None of this is a forecast, a fair value or a target.

Hurdle rate	Profit the price needs	× FY26 profit	Years at 15% growth	Years at 25% growth
10% a year	₹897 cr	5.5x	12.2	7.6
12% a year	₹1,076 cr	6.6x	13.5	8.4
14% a year	₹1,256 cr	7.6x	14.6	9.1

Earnings yield at the upper band: 1.83% (FY26 profit ÷ market value).
Free cash flow yield: 0.00% (operating cash flow less capital expenditure, ₹0.4 cr, ÷ market value).

The Formula NotebookEvery number above, with the working shown. Check us.

Every number we publish, with the working shown. The formula, the same formula with this company’s actual figures put into it, the answer, and what it is for. Check us. That is the point.

Profitability

Return on Equity (ROE)14.3%

FormulaPAT ÷ Net Worth

Worked164.14 ÷ 1,144.68

What the company earned on the money shareholders have in it. The headline measure of return — and the one the DuPont section takes apart.

Return on Capital Employed (ROCE)17%

FormulaEBIT ÷ (Net Worth + Total Borrowings)

Worked264.60 ÷ (1,144.68 + 412.64) = 264.60 ÷ 1,557.31

Return on ALL the capital in the business, borrowed as well as owned. Unlike ROE, it cannot be flattered by taking on debt.

EBITDA Margin22.6%

FormulaEBITDA ÷ Revenue

Worked328.24 ÷ 1,445.69

Operating profitability before the effects of debt, tax and depreciation. What the business earns from the act of trading.

Leverage

Debt to Equity0.36x

FormulaTotal Borrowings ÷ Net Worth

Worked412.64 ÷ 1,144.68

How much the company has borrowed against what it owns. High is not automatically bad — ask whether the borrowing is being serviced comfortably.

Interest Coverage7.91x

FormulaEBIT ÷ Finance Cost

Worked264.60 ÷ 33.47

How many times over operating profit covers the interest bill. Below about 2x, a meaningful share of what the business earns is going to lenders rather than owners.

Efficiency

Receivable Days103 days

Formula(Trade Receivables ÷ Revenue) × 365

Worked(408.74 ÷ 1,445.69) × 365

How long the company waits to be paid. Rising receivable days mean revenue is being booked faster than it is collected — which is where a great many accounting problems begin.

Cash Conversion Cycle263 days

FormulaInventory Days + Receivable Days − Payable Days

Worked288 + 103 − 128

How long cash is tied up in the operating cycle before it comes back. The longer it is, the more working capital the business must fund.

Quality of Earnings

Operating Cash Flow to Profit0.31x

FormulaCash from Operations ÷ PAT

Worked50.39 ÷ 164.14

Did the profit turn into cash? Profit is an opinion; cash is a fact. When this sits well below 1x for long, the two are drifting apart, and the filing is where you find out why.

Accruals Ratio5.3%

Formula(PAT − Cash from Operations) ÷ Total Assets

Worked(164.14 − 50.39) ÷ 2,148.42 = 113.76 ÷ 2,148.42

The share of reported profit that exists on paper rather than in the bank. It is also the heaviest single term in the Beneish model, for good reason.

Valuation at the Offer Price

Market Capitalisation (at the top of the band)₹8,968.25 cr

FormulaPrice × Post-issue Shares

Worked₹807.00 × 111,130,670 shares

What the whole company is being valued at, if the issue prices at the top of the band.

Enterprise Value (EV)₹9,025.35 cr

FormulaMarket Cap + Total Borrowings − Cash

Worked8,968.25 + 412.64 − 355.53

What it would actually cost to buy the whole business: you take on its debt and you get its cash. This is the number a buyer cares about, and it is the reason a P/E on its own can mislead.

EV / EBITDA27.5x

FormulaEnterprise Value ÷ EBITDA

Worked9,025.35 ÷ 328.24

The multiple that includes debt. Two companies on the same P/E — one debt-free, one heavily borrowed — are not the same investment, and only this number tells you so.

Price / Earnings (P/E)54.64x

FormulaMarket Cap ÷ PAT

Worked8,968.25 ÷ 164.14

The familiar multiple. Useful, but blind to debt — read it alongside EV/EBITDA, never instead of it.

Return on Invested Capital (ROIC)15.6%

FormulaEBIT × (1 − tax rate) ÷ (Net Worth + Debt − Cash)

WorkedNOPAT ÷ Invested Capital

What the business earns on the capital actually at work in it. We do not compare this to a cost of capital: that would need a beta, an unlisted company has none, and inventing one would be theatre.

Earnings yield at the upper band1.83%

FormulaLatest full-year PAT ÷ market value

Worked₹164.14 cr ÷ ₹8,968.25 cr

The P/E turned upside down: what each rupee of market value earns today. Set it against what you could earn elsewhere; the gap is what growth has to make up.

Free cash flow yield at the upper band0.00%

Formula(Operating cash flow − capital expenditure) ÷ market value

Worked₹0.36 cr ÷ ₹8,968.25 cr

Cash left after the company pays for its own investment, against the price of the whole company. Profit can be shaped by accounting choices; this is harder to shape.

Trailing PEG — read the caveat2.96 (on 18.4% trailing growth)

FormulaP/E ÷ trailing PAT growth (%)

Worked54.64 ÷ 18.4%

PEG was designed for FORWARD growth. This one uses TRAILING growth, because that is all a prospectus gives us — and the final year before an IPO is very often the best year the company will have for a while. A low PEG here may say more about the timing of the filing than about the price. We show it because it was asked for; we show the growth denominator beside it so it cannot mislead you quietly.

FinMinutes IPO HubEvery live and upcoming issue, scored the same way, on one page.All IPOs →

Workspace

The post-issue share count is stated as “[•]” in this filing until final pricing, so we derive it: profit after tax divided by earnings per share gives the pre-issue count, and the fresh issue divided by the offer price gives the new shares. Everything below rests on that derivation. It is close, not exact.

The numbers are already loaded. Move the offer price and watch every multiple move with it. Set your own growth and margin and see what they imply two years out. These are your assumptions, not our forecast — we have no view on what this company will earn, and the moment we published one we would be doing something we are not registered to do. What we can do is put the arithmetic in front of you and get out of the way.

Price per share (₹)

Revenue growth, per year (%)

EBITDA margin held at (%)

Discount rate for the reverse DCF (%)

Price defaults to the top of the band. Margin defaults to what the company actually reported in FY26.

Market capitalisation—

Enterprise value—

P / E—

EV / EBITDA—

EV / Sales—

On your assumptions, two years out

Revenue—

EBITDA—

Implied forward EV / EBITDA—

What the price is assuming

Free-cash growth priced in, 10 yrs—

Years to earn back the market cap—

Projections are arithmetic on the inputs you typed. They are not a forecast, not a recommendation, and not a view on whether this offer is worth taking. Educational only.

Institutional Alpha: DRHP Deep Dive

Industry Overview (RHP p. 175, 215, 219)

According to the 1Lattice Report, the global point-of-care testing (POCT) market is experiencing rapid expansion, driven by the increasing relevance of near-patient diagnostics, which offer faster turnaround times, lower capital costs, and ease of use in resource-limited or decentralized settings. Electrification and battery operation are crucial for penetration in emerging economies. Molecular diagnostics represents a highly competitive yet high-barrier space characterized by intensive R&D, stringent regulatory clearances (such as ICMR and WHO), and oligopolistic structures. Key growth areas include infectious disease screening (such as TB and COVID-19) and non-communicable diseases. Established players with strong technological IP, razor-and-blade recurring revenue profiles, and validated manufacturing capabilities are well-positioned to capitalize on this shift from centralized laboratory testing.

Market SizeUSD 29.3 billion (equivalent to ₹ 2,588.6 billion) (Global POCT Market) Growth17.9% CAGR between 2025 and 2030

Future Planning & Capital Allocation

The company’s capital allocation strategy focuses heavily on long-term capabilities rather than immediate capacity. It allocates ₹105.54 crore of its Fresh Issue proceeds for setting up research and development infrastructure and a Center of Excellence through subsidiary Bigtec, alongside ₹72.28 crore for procurement of plant and machinery to expand and automate facilities in Goa and Visakhapatnam.

Source: RHP p. 37, 128-129

Competitive Position

Molbio holds an oligopolistic competitive position secured by WHO and ICMR approvals for molecular diagnostics. Being one of only two globally approved point-of-care TB diagnostic platforms provides immense pricing power and bidding advantages in public tender programs.

Source: RHP p. 142, 215, 219

Execution / Track Record

The company has demonstrated robust growth, scaling consolidated revenue from operations from ₹836.56 crore in FY24 to ₹1,445.69 crore in FY26. Concurrently, test kit volumes scaled from 8.80 million to 17.56 million, proving strong commercialization traction.

Source: RHP p. 79, 315-316, 375

Shareholding, Syndicate & Leadership

Promoter Pre → Post46.65% → —%

Pledged Shares0%

Free Float—%

Anchor—

Merchant Bankers (BRLMs)Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited

RegistrarKFin Technologies Limited

Leadership & Skin in the Game

Leadership: Sriram Natarajan

Litigation: Outstanding tax claims against the Company total 11 cases involving an aggregate disputed amount of ₹507.81 million (comprising ₹235.02 million in direct taxes and ₹272.79 million in indirect taxes). In addition, Promoter Sriram Natarajan has 1 pending direct tax dispute involving ₹46.03 million. Pending criminal proceedings filed by the Company and its subsidiaries total ₹188.89 million.

Auditor / RPT Flags: Statutory auditors included emphasis of matter paragraphs regarding a ₹199.00 million EMD fraud in subsidiary Prognosys Medical Systems and audit modifications/qualifications regarding unenabled database-level audit trails, disabled edit logs, and missing daily offsite server backups of electronic books of account. Significant related party transactions include a ₹1,233.62 million royalty expense paid to Bigtec Private Limited in FY26.

Peers & Valuation

Company	P/E	P/B	RoE	Margin
Poly Medicure Limited	52.61	—	10.37	—
Dr. Lal Pathlabs Limited	62.2	—	20.78	—
Metropolis Healthcare Limited	63.72	—	12.56	—
Vijaya Diagnostics Centre Limited	81.02	—	18.07	—

Where this sits

At the ₹807 upper band, the issue is priced at 54.6x earnings — a 13% discount to the peer median of 63.0x. This is the arithmetic of the price band against the peers the filing itself lists; it is not a view on whether the offer is worth taking.

🔍 Forensic Findings — What the Footnotes Say

Findings from across the filing — the notes, MD&A, related-party disclosures, contingent liabilities, CARO and litigation, alongside the risk section itself. Each carries where it was found, so you can see which were buried and which were disclosed. Findings marked derived are computed from the filed numbers against a stated rule, shown beside them.

Audit Trail (Edit Log) Gaps and Backup Failures where: footnotes flagged

Statutory auditors reported that the audit trail (edit log) feature in core accounting software was not enabled at the database level or for certain transactions, and records were not preserved for prior years. In addition, backup of books of accounts in electronic mode was not maintained on servers physically located in India on a daily basis for certain periods.

RHP p. 419, 420, 422, 428, 782, 784

Intermediary Fund Routing where: footnotes flagged

Statutory auditors noted that in FY24, the Group advanced ₹60.00 million to Chayagraphics (India) Private Limited, which acted as an intermediary to further advance ₹58.62 million to the ultimate beneficiary (a shareholder of Chayagraphics Healthcare Private Limited).

RHP p. 422, 502, 724, 725, 785

Discrepancies in Bank Stock and Debt Statements where: footnotes flagged

The quarterly returns comprising stock and book debt statements filed by the Company and its subsidiary (Prognosys Medical Systems) with banks cannot be reconciled with audited/reviewed books of account or are not in agreement with books of account due to timing differences in passing entries.

RHP p. 507, 517, 518, 563, 564, 786, 790, 795

Multiple Prior Employee and Vendor Frauds where: other flagged

The statutory reports highlight that (i) two external parties misappropriated ₹4.43 million from the Company in FY25; (ii) an employee of Bigtec misappropriated ₹6.09 million in FY24 via unauthorized payments for fake/inflated purchase orders; and (ii) subsidiary Prognosys Medical Systems suffered a ₹199.00 million fraud regarding misappropriation of earnest money deposits (EMD) prior to acquisition.

RHP p. 36, 109, 110, 417, 779, 792, 797

Government and Aid Agency Revenue Concentration where: risk_section noted

The company derives a substantial portion of finished goods contract revenues from public healthcare programs of Indian central/state governments and international aid agencies, contributing 84.56% in FY26, 87.83% in FY25, and 91.60% in FY24.

RHP p. 28, 368

Material Uncertainty Over Subsidiary Financial Viability where: footnotes noted

Statutory auditors reported that material uncertainty exists regarding the capability of subsidiaries Prognosys Medical Systems and Prognosys Healthcare (India) to meet their liabilities as they fall due within one year.

RHP p. 524, 526, 540, 541, 789, 793, 798

Material Litigation where: litigation flagged

Outstanding tax claims against the Company total 11 cases involving an aggregate disputed amount of ₹507.81 million (comprising ₹235.02 million in direct taxes and ₹272.79 million in indirect taxes). In addition, Promoter Sriram Natarajan has 1 pending direct tax dispute involving ₹46.03 million. Pending criminal proceedings filed by the Company and its subsidiaries total ₹188.89 million.

RHP p. 22, 28, 36, 62, 84, 88, 101, 110, 137, 417, 419, 420, 422, 425, 426, 428, 803, 828, 836

Auditor / RPT Notes where: rpt flagged

Statutory auditors included emphasis of matter paragraphs regarding a ₹199.00 million EMD fraud in subsidiary Prognosys Medical Systems and audit modifications/qualifications regarding unenabled database-level audit trails, disabled edit logs, and missing daily offsite server backups of electronic books of account. Significant related party transactions include a ₹1,233.62 million royalty expense paid to Bigtec Private Limited in FY26.

RHP p. 22, 28, 36, 62, 84, 88, 101, 110, 137, 417, 419, 420, 422, 425, 426, 428, 803, 828, 836

Company's Claims vs Reality

We stress-test each claim against the filing's own data.

We have a scalable business model with strong entry barriers and a high proportion of recurring revenues driven by our Truenat molecular diagnostic platform. Supported

Do restated financials and sales volumes verify a highly recurring razor-and-blade model?

RHP p. 218, 315, 375 (Revenues from sale of test kits scaled to ₹10,348.20 million or 71.58% of FY26 operations, driven by 17.56 million kits sold, whereas device sales were ₹2,032.84 million, supporting a highly recurring blade revenue structure)

The company possesses strong entry barriers based on R&D focus and unique regulatory/WHO clearances. Supported

Does independent industry research confirm the exclusivity of the WHO clearances?

RHP p. 142, 215, 219 (Our Truenat test chip is the only molecular test developed by an Indian company, and one of only two globally, endorsed by the WHO for initial diagnosis of TB and rifampicin resistance, which was obtained after 13 years of R&D)

Proprietary SWOT — Company-Specific

Strengths

WHO-endorsed flagship Truenat PCR platform, representing a critical, highly validated tool for global tuberculosis screening.
Highly cash-generative razor-and-blade model with test kits driving 71.58% of consolidated operating revenues in FY26.

Weaknesses

Extreme reliance on public health channels, with 84.56% of finished goods revenue tied to government programs and international aid agencies.
Underperforming subsidiaries including OptraScan INC and Prognosys Healthcare which incurred net losses in FY26.

Opportunities

Substantial test menu expansion, with plans to launch 34 additional assays for 22 diseases.
Strategic entry into highly regulated overseas markets, particularly Western Europe and the United States.

Threats (material, not boilerplate)

Changes in government funding or policy priorities for public health programs. risk_section
Why it matters: Because 84.56% of finished goods revenue is government-dependent, any funding freeze or budget realignment directly impacts product sales.
Significant cash flow impact from pending direct and indirect tax disputes totaling ₹507.81 million. litigation
Why it matters: An adverse final ruling in these tax proceedings would require substantial cash outflows, impacting liquidity.

Live Subscription Status

Total81.7x

Total subscription is fed live from the exchange data feed. The category split (QIB, NII, retail) is not carried by that feed and is added by hand where it is material — so it is shown only when we have actually verified it, rather than left as blanks.

Allotment Status

Bidding closed12 Aug 2026

Allotment14 Aug 2026

Refunds begin14 Aug 2026

Listing17 Aug 2026

Check your allotment on the registrar's portal → Registrar: KFin Technologies

Allotment is decided by the registrar, not by us and not by the exchange. In an oversubscribed retail book, allotment is by lottery, so a large application does not improve your odds beyond one lot. If money stays blocked after the refund date, the mandate expiry (23 Sep 2026) is the date to raise with your bank.

Analyst Q&A: Burning Questions

Facts from the filing. No recommendation — that layer arrives once our Research Analyst registration is live.

USE OF PROCEEDS

Where is the money going?

The Net Proceeds from the ₹200.00 crore Fresh Issue are being deployed towards capital expenditure. Specifically, ₹105.54 crore is allocated for setting up research and development infrastructure and a Center of Excellence for wholly-owned subsidiary Bigtec, and ₹72.28 crore is earmarked for purchasing plant, machinery, and automation equipment for manufacturing units in Goa and Visakhapatnam.

RHP p. 37, 128-129

CONCENTRATION

How concentrated is the customer base?

The customer base is highly concentrated. The top 10 customers contributed 83.26% of finished goods sales in FY26 (compared to 83.62% in FY25 and 78.54% in FY24). Additionally, finished goods sales to central/state government healthcare programs and international aid agencies represented 84.56% of total contract sales in FY26.

RHP p. 28, 368

PROFITABILITY

Is it profitable and growing?

Yes. Revenue from operations increased from ₹836.56 crore in FY24 to ₹1,020.42 crore in FY25, and scaled to ₹1,445.69 crore in FY26. Consolidated net profit (PAT) was ₹83.54 crore in FY24, ₹138.58 crore in FY25, and ₹164.14 crore in FY26, maintaining an EBITDA margin of 22.56% in FY26.

RHP p. 79, 316, 371

HIDDEN RISKS

What sits in the footnotes / contingent liabilities?

As of March 31, 2026, contingent liabilities total ₹1,687.42 million (comprising bank guarantees of ₹900.98 million, direct tax disputes of ₹461.48 million, indirect tax disputes of ₹322.37 million, and other claims of ₹2.59 million). Footnotes also disclose outstanding Income Tax department demands of ₹234.17 million following a survey under Section 133A, along with recurring statutory auditor exceptions regarding unenabled database-level audit trails and missing daily local server backups.

RHP p. 62, 84, 175, 419, 420, 425, 426, 428, 782, 803

GMP: ₹110 — unofficial grey-market chatter, shown for information only. Never part of the FinMinutes Score.

What Earlier Investors Paid

Early capital takes real risk and is fairly rewarded for it — a large multiple built over many years is normal. What deserves a closer look is a steep step-up in a short window: a round priced cheaply only months before the offer.

Shareholder	Priced at	When	vs IPO price
Shankar Gopalkrishnan	₹651.46	2024-09-03	1.2x
Allotted below the band — 3 entries
India Business Excellence Fund III	₹7,248.70	2021-05-31	as disclosed
India Business Excellence Fund III	₹7,248.70	2021-05-31	as disclosed
V Sciences Investments Pte. Ltd.	₹54,495.91	2022-09-23	as disclosed

The 3 allotments listed under “allotted below the band” are shown at their as-disclosed per-share price. They are not adjusted for any later bonus issue or share split, so where a company has issued bonus shares the raw multiple understates the true return and can even read as a loss when none was made. We show them as filed and decline to compute a misleading multiple.

Prices are as stated in the filing’s allotment history and are not adjusted for later bonus issues or share splits. Where a company has issued bonus shares, the multiples above understate the true return and can even read as losses. Adjusting for that is on our list; until it is done we would rather show the raw disclosure and tell you its limits than publish a confident number that is wrong.

Lock-in Expiry Calendar

Shares held before the IPO cannot be sold immediately; they unlock in tranches. When a tranche unlocks, more shares become eligible to trade. Retail investors are frequently caught unaware by these dates. The schedule below follows from the listing date; quantities are shown only where the filing discloses them.

17 Aug 2029
Minimum Promoters' Contributionthree years
17 Aug 2027
Promoters' shareholding in excess of Minimum Promoters' Contributionone year
17 Feb 2027
Entire pre-Offer equity share capitalsix months
15 Nov 2026
Anchor Investors (50%)90 days
16 Sep 2026
Anchor Investors (50%)30 days

An unlock means more shares may be sold — not that they will be, and not that the price will move. We state the dates; what you do with them is your call.

What Changed Between the DRHP and the RHP

Companies file a draft prospectus, then a final one. The changes in between are rarely reported, and they can be revealing.

Item	In the DRHP	In the RHP / Addendum
Offer for Sale (OFS) Share Volume The Offer for Sale size was reduced by 3,390,000 Equity Shares (representing a 27.00% reduction), while the Fresh Issue component remained unchanged at up to ₹ 2,000.00 million.	Up to 12,556,000 Equity Shares	Up to 9,166,000 Equity Shares
Financial Information Period The financial disclosures were rolled forward to include full Fiscal 2026 financials, dropping the oldest reporting year (Fiscal 2023).	Restated Consolidated Summary Statements for Fiscals 2025, 2024 and 2023	Restated Consolidated Summary Statements for Fiscals 2026, 2025 and 2024
Chief Financial Officer The company appointed Manan Bimal Khokhani as the new Chief Financial Officer, replacing Amol Narayan Lone, effective December 22, 2025.	Amol Narayan Lone	Manan Bimal Khokhani
Use of Proceeds (CAPEX for R&D facility and Center of Excellence) The proposed allocation from Net Proceeds for setting up the R&D facility and Center of Excellence was increased by ₹ 61.67 million.	Up to ₹ 993.68 million	Up to ₹ 1,055.35 million
Weighted Average Cost of Acquisition (WACA) in preceding 1 Year The weighted average cost of acquisition of shares transacted in the 1 year preceding the prospectus increased from ₹ 1,042.95 to ₹ 1,090.00, reflecting secondary transactions executed up to October 4, 2025.	₹ 1,042.95 per share	₹ 1,090.00 per share

Educational, grounded entirely in the company's filings (DRHP/RHP). Not investment advice. FinMinutes does not provide buy/sell recommendations.

Written and verified by

Gaureesh Vats Shukla

Founder and Head of Research, FinMinutes

Gaureesh Vats Shukla reads Indian offer documents as an engineer. He has read several hundred of them alongside annual reports, most of them by hand before he built the structured extraction engine that now does the work at scale, and every figure on this page carries a citation back to the page of the filing it came from. To restated numbers he applies a standard forensic battery: Beneish M-score, Altman Z-double-prime, Piotroski F-score, DuPont decomposition and cash-conversion analysis. Coverage runs the full cap spectrum alongside macro, mutual funds and unlisted companies, with particular depth in the segment institutional research does not reach. The sectors closest to the work are defence and aerospace, semiconductors and electronics, technology, engineering and EPC, solar and capital goods. He holds a B.Tech in Aerospace Engineering and completed the Post Graduate Programme in Securities Markets at NISM with a research analysis specialisation.

The same research method is available as commissioned work: company diligence, industry and market-entry studies, and financial modelling. See what that covers →

Figures on this page were last recomputed from the filing on 2026-10-21.

Molbio Diagnostics IPO GMP Today and a Deep Forensic Analysis